---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-121824"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2025-05-16T23:59:59+00:00"
generated_at: "2026-05-21T03:17:03.908725+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Atara Biotherapeutics raises ~$16M in registered direct offering of common stock and pre-funded warrants

## Summary
- Gross proceeds ~$16M from 834,237 shares at $6.61/share and pre-funded warrants for 1,587,108 shares at $6.6099.
- Pre-funded warrants have exercise price $0.0001/share, exercisable immediately, no expiration.
- Net proceeds to fund BLA approval activities for tab-cel and for working capital.
- Underwriting agreement with TD Securities; offering expected to close May 16, 2025.
- 30-day lock-up on issuance and sale of company securities post-closing.

## SEC filing metadata
- accession: 0001193125-25-121824
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2025-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000119312525121824/0001193125-25-121824-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000119312525121824/d45771d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-121824
- JSON: https://secwatch.observer/filing/0001193125-25-121824.json
- Plain text: https://secwatch.observer/filing/0001193125-25-121824.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.